Avient Corporation vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Avient Corporation trades at $45.51 (market cap $4.19B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 2.2× Avient Corporation's market cap, and Avient Corporation pays a 2.41% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| AVNT | BIO | |
|---|---|---|
Market Cap | $4.19B | $9.39B |
Sector | Technology | Health |
52-Week High | $45.69 | $356.25 |
52-Week Low | $27.48 | $241.71 |
Enterprise Value | $5.64B | $9.14B |
Dividend Yield | 2.41% | — |
Signals from Pluang's Aura AI — not financial advice
Avient Corporation (AVNT) trades at $45.69, up 7.13% with strong technical momentum. The stock shows consistent earnings beats with Q2 2026 EPS of $0.96 exceeding expectations by $0.07. Analyst consensus remains bullish with a $49.00 price target and 60% buy ratings. Recent quarterly dividend of $0.275 per share demonstrates shareholder returns while maintaining operational strength with $299M operating cash flow in 2026.
Outlook remains positive with improved full-year guidance and 20% adjusted EPS growth. Key risks include competitive pressures in chemical sector and potential margin compression. Upside potential exists toward $49-50 resistance zone, supported by strong fundamentals and institutional confidence in management's execution capabilities.
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Trailing returns across standard periods
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →